Csenge Advisory Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Csenge Advisory Group’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4	Closed	–	–	566
2018 Q3	$0	Buy	+4	New	+$401	﹤0.01%	1191

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Csenge Advisory Group's ENTA Position: Q4 2018 in Review

Csenge Advisory Group sold out of Enanta Pharmaceuticals (ENTA) in Q4 2018, closing a stake of 4 shares.

Csenge Advisory Group first reported a position in ENTA in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 183 funds tracked by Wall St. Rank hold ENTA as of Q4 2018.

Csenge Advisory Group reported no remaining Enanta Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Csenge Advisory Group sold 4 Enanta Pharmaceuticals shares in Q4 2018.
Csenge Advisory Group first reported a position in Enanta Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Csenge Advisory Group's Enanta Pharmaceuticals position peaked at $0 in Q3 2018.
183 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.